ES2439244T8 - Inhibidores de serina proteasa tipo tripsina, su preparación y uso - Google Patents

Inhibidores de serina proteasa tipo tripsina, su preparación y uso Download PDF

Info

Publication number
ES2439244T8
ES2439244T8 ES07819274.7T ES07819274T ES2439244T8 ES 2439244 T8 ES2439244 T8 ES 2439244T8 ES 07819274 T ES07819274 T ES 07819274T ES 2439244 T8 ES2439244 T8 ES 2439244T8
Authority
ES
Spain
Prior art keywords
trypsin
preparation
protease inhibitors
serine protease
serine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07819274.7T
Other languages
English (en)
Other versions
ES2439244T3 (es
Inventor
Torsten Steinmetzer
Andrea Schweinitz
Jörg STÜRZEBECHER
Peter Steinmetzer
Anett SÖFFING
Andreas Van De Locht
Silke Nicklisch
Claudia Reichelt
Friedrich-Alexander Ludwig
Alexander Schulze
Mohammed Daghish
Jochen Heinicke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medicines Company Leipzig GmbH
Original Assignee
Medicines Company Leipzig GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicines Company Leipzig GmbH filed Critical Medicines Company Leipzig GmbH
Application granted granted Critical
Publication of ES2439244T3 publication Critical patent/ES2439244T3/es
Publication of ES2439244T8 publication Critical patent/ES2439244T8/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pyridine Compounds (AREA)
  • Materials For Medical Uses (AREA)
ES07819274.7T 2006-10-24 2007-10-24 Inhibidores de serina proteasa tipo tripsina, su preparación y uso Active ES2439244T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102006050672A DE102006050672A1 (de) 2006-10-24 2006-10-24 Hemmstoffe des Plasmins und des Plasmakallikreins
DE102006050672 2006-10-24
PCT/EP2007/009220 WO2008049595A1 (de) 2006-10-24 2007-10-24 Trypsinartige serinprotease-hemmstoffe, ihre herstellung und verwendung

Publications (2)

Publication Number Publication Date
ES2439244T3 ES2439244T3 (es) 2014-01-22
ES2439244T8 true ES2439244T8 (es) 2014-11-06

Family

ID=38961973

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07819274.7T Active ES2439244T3 (es) 2006-10-24 2007-10-24 Inhibidores de serina proteasa tipo tripsina, su preparación y uso

Country Status (14)

Country Link
US (3) US8207378B2 (es)
EP (2) EP2054380B8 (es)
JP (1) JP5356237B2 (es)
CN (1) CN101541742A (es)
AU (1) AU2007308421B2 (es)
BR (1) BRPI0718286A2 (es)
CA (1) CA2667507C (es)
DE (1) DE102006050672A1 (es)
EA (1) EA018998B1 (es)
ES (1) ES2439244T3 (es)
MX (1) MX2009004320A (es)
NO (1) NO20091647L (es)
NZ (1) NZ577008A (es)
WO (1) WO2008049595A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2478409C (en) * 2002-03-11 2012-07-31 Curacyte Ag Inhibitors of urokinase, their preparation and use
DE10301300B4 (de) * 2003-01-15 2009-07-16 Curacyte Chemistry Gmbh Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein
DE102005044319A1 (de) * 2005-09-16 2007-03-22 Curacyte Chemistry Gmbh 2-(Aminomethyl)-5-Chlor-Benzylamid-Derivate und ihre Verwendung als Hemmstoffe des Gerinnungsfaktors Xa
DE102006050672A1 (de) 2006-10-24 2008-04-30 Curacyte Discovery Gmbh Hemmstoffe des Plasmins und des Plasmakallikreins
US8865865B2 (en) 2008-10-29 2014-10-21 Philipps-Universitat Marburg N-terminally modified tetrapeptide derivatives having a C-terminal arginine mimetic
CA2788417C (en) * 2010-01-28 2017-02-14 The Medicines Company (Leipzig) Gmbh Trypsin-like serine protease inhibitors, and their preparation and use
EP2590945B1 (en) 2010-07-07 2014-04-30 The Medicines Company (Leipzig) GmbH Serine protease inhibitors
AU2011305617A1 (en) * 2010-09-20 2013-02-21 Sirna Therapeutics, Inc. Novel low molecular weight cationic lipids for oligonucleotide delivery
EP2655399B1 (en) 2010-12-21 2017-09-27 The Medicines Company (Leipzig) GmbH Trypsin-like serine protease inhibitors, their preparation and use as selective inhibitors of the clotting factors iia and xa
GB2494851A (en) 2011-07-07 2013-03-27 Kalvista Pharmaceuticals Ltd Plasma kallikrein inhibitors
EP2543676A1 (de) 2011-07-07 2013-01-09 Philipps-Universität Marburg Zyklische Tripeptidmimetika
GB201212081D0 (en) 2012-07-06 2012-08-22 Kalvista Pharmaceuticals Ltd New polymorph
IL239682B (en) 2013-01-08 2018-10-31 Kalvista Pharmaceuticals Ltd History of benzylamine and 2-(aminomethyl)pyridine
GB201300304D0 (en) 2013-01-08 2013-02-20 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
GB2510407A (en) 2013-02-04 2014-08-06 Kalvista Pharmaceuticals Ltd Aqueous suspensions of kallikrein inhibitors for parenteral administration
MY174018A (en) 2013-05-23 2020-03-04 Kalvista Pharmaceuticals Ltd Heterocyclic derivates
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
EP3033336B1 (en) 2013-08-14 2018-05-30 Kalvista Pharmaceuticals Limited Inhibitors of plasma kallikrein
GB2517908A (en) 2013-08-14 2015-03-11 Kalvista Pharmaceuticals Ltd Bicyclic inhibitors
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
GB201421088D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
KR20160111657A (ko) 2015-03-17 2016-09-27 김순철 절수형 변기
RS60600B1 (sr) 2016-05-31 2020-08-31 Kalvista Pharmaceuticals Ltd Derivati pirazola kao inhibitori kalikreina plazme
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
PL3716952T3 (pl) 2017-11-29 2022-05-02 Kalvista Pharmaceuticals Limited Postacie dawkowania zawierające inhibitor kalikreiny osoczowej
GB201910125D0 (en) 2019-07-15 2019-08-28 Kalvista Pharmaceuticals Ltd Treatments of angioedema
GB201910116D0 (en) 2019-07-15 2019-08-28 Kalvista Pharmaceuticals Ltd Treatments of hereditary angioedema
CN114206852A (zh) 2019-08-09 2022-03-18 卡尔维斯塔制药有限公司 血浆激肽释放酶抑制剂
GB201918994D0 (en) 2019-12-20 2020-02-05 Kalvista Pharmaceuticals Ltd Treatments of diabetic macular edema and impaired visual acuity
GB2591730A (en) 2019-12-09 2021-08-11 Kalvista Pharmaceuticals Ltd New polymorphs
WO2022079446A1 (en) 2020-10-15 2022-04-21 Kalvista Pharmaceuticals Limited Treatments of angioedema
US20230381162A1 (en) 2020-10-23 2023-11-30 Kalvista Pharmaceuticals Limited Treatments of angioedema
WO2022172006A1 (en) 2021-02-09 2022-08-18 Kalvista Pharmaceuticals Limited Treatments of hereditary angioedema
WO2023002219A1 (en) 2021-07-23 2023-01-26 Kalvista Pharmaceuticals Limited Treatments of hereditary angioedema
DK4288036T3 (da) 2022-04-27 2024-08-26 Kalvista Pharmaceuticals Ltd Formuleringer af en plasmakallikreinhæmmer

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0183271B1 (en) 1984-11-30 1990-05-16 Shosuke Okamoto Lysin derivative and proteinase inhibitor
KR920703558A (ko) * 1990-11-15 1992-12-18 원본미기재 메타-치환 페닐알라닌 유도체
DE4243858A1 (de) 1992-12-23 1994-06-30 Thomae Gmbh Dr K Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE59410179D1 (de) 1993-02-10 2002-10-10 Pentapharm Ag Basel Piperazide von substituierten phenylalanin-derivativen als thrombin inhibitoren
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
US5550213A (en) 1993-12-27 1996-08-27 Rutgers, The State University Of New Jersey Inhibitors of urokinase plasminogen activator
CA2140598C (en) 1994-01-27 2010-03-09 Masahiro Ohshima Prolineamide derivatives
US5726159A (en) * 1994-03-04 1998-03-10 Eli Lilly And Company Antithrombotic agents
US5707966A (en) * 1994-03-04 1998-01-13 Eli Lilly And Company Antithrombotic agents
US5705487A (en) * 1994-03-04 1998-01-06 Eli Lilly And Company Antithrombotic agents
ZA951617B (en) 1994-03-04 1997-02-27 Lilly Co Eli Antithrombotic agents.
CA2186497C (en) 1994-04-26 2008-06-17 Fahad Al-Obeidi Factor xa inhibitors
NZ302649A (en) 1995-02-17 2000-01-28 Basf Ag Dipeptide amidine derivatives, preparation and pharmaceutical compositions thereof
US5710130A (en) * 1995-02-27 1998-01-20 Eli Lilly And Company Antithrombotic agents
US5914319A (en) * 1995-02-27 1999-06-22 Eli Lilly And Company Antithrombotic agents
CH689611A5 (de) 1995-03-01 1999-07-15 Pentapharm Ag Urokinase-Inhibitoren.
US5786328A (en) * 1995-06-05 1998-07-28 Genentech, Inc. Use of kunitz type plasma kallikrein inhibitors
TWI238827B (en) 1995-12-21 2005-09-01 Astrazeneca Ab Prodrugs of thrombin inhibitors
AU3496297A (en) * 1996-06-25 1998-01-14 Eli Lilly And Company Anticoagulant agents
ZA986594B (en) 1997-07-25 1999-01-27 Abbott Lab Urokinase inhibitors
JP4603162B2 (ja) 1998-07-20 2010-12-22 ヴィレックス アクチェンゲゼルシャフト 新規ウロキナーゼインヒビター
US7342018B2 (en) * 1998-07-20 2008-03-11 Wilex Ag Urokinase inhibitors and uses thereof
US6576613B1 (en) 1998-07-24 2003-06-10 Corvas International, Inc. Title inhibitors of urokinase
SE9802974D0 (sv) 1998-09-03 1998-09-03 Astra Ab New crystalline forms
ES2188003T3 (es) 1998-09-18 2003-06-16 Pentapharm Ag Inhibidores de la uroquinasa.
ATE307111T1 (de) 1999-01-13 2005-11-15 Genentech Inc Serinprotease-inhibitoren
FR2791683A1 (fr) * 1999-03-30 2000-10-06 Synthelabo Derives de n-sulfonyl-dipeptides, leur preparation et leur application en therapeutique
AR023510A1 (es) 1999-04-21 2002-09-04 Astrazeneca Ab Un equipo de partes, formulacion farmaceutica y uso de un inhibidor de trombina.
DE19940389A1 (de) * 1999-08-25 2001-03-01 Wilex Biotechnology Gmbh Selektive Inhibitoren des Urokinase-Plasminogen Aktivators
US6797504B1 (en) 2000-09-08 2004-09-28 Dendreon San Diego Llc Inhibitors of serine protease activity of matriptase or MTSP1
DE10005631A1 (de) * 2000-02-09 2001-08-23 Max Planck Gesellschaft Arginin-Mimetika als Faktor X¶a¶-Inhibitoren
DE10013715A1 (de) * 2000-03-20 2001-09-27 Wilex Biotechnology Gmbh Hochselektive Inhibitoren des Urokinase-Plasminogenaktivators
DE60117783T2 (de) 2000-04-25 2006-11-30 Abbott Laboratories, Abbott Park Naphthamidin-urokinaseinhibitoren
DE10029014A1 (de) 2000-06-15 2001-12-20 Univ Schiller Jena Urokinase-Hemmstoffe
DE10029015A1 (de) 2000-06-15 2001-12-20 Curacyte Ag Hemmstoffe für den Gerinnungsfaktor Xa
DE10029001C2 (de) 2000-06-17 2003-03-27 Rainer Seidel Automatische Warnvorrichtung vor einer kritischen Schiffsneigung z.B. bei Wellenbildung oder Krängung
AU2001266838A1 (en) 2000-06-21 2002-01-02 Georgetown University Inhibitors of matriptase for the treatment of cancer
WO2002006280A2 (en) 2000-07-13 2002-01-24 Millennium Pharamaceuticals, Inc. INHIBITORS OF FACTOR Xa
EP1182207B1 (en) * 2000-08-11 2007-04-18 Dendreon Corporation Non-covalent inhibitors of urokinase and blood vessel formation
CA2387002A1 (en) 2000-08-11 2002-02-21 Corvas International, Inc. Non-covalent inhibitors of urokinase and blood vessel formation
CA2431588A1 (en) 2000-12-18 2002-06-27 Merck & Co., Inc. Benzylamine derivatives and their use as thrombin inhibitors
DE10102878A1 (de) * 2001-01-23 2002-08-01 Haemosys Gmbh Oligo- oder Polyalkylengekoppelte Thrombininhibitoren
WO2002062829A1 (fr) 2001-02-02 2002-08-15 Chugai Seiyaku Kabushiki Kaisha Derives de peptide
DE50209313D1 (de) * 2001-12-12 2007-03-08 Wilex Ag Selektive arylguanidinpeptide als urokinaseinhibitoren
AU2003206945A1 (en) * 2002-02-22 2003-09-09 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Use of proteinase inhibitors in the treatment of autoimmune diseases
CA2478409C (en) * 2002-03-11 2012-07-31 Curacyte Ag Inhibitors of urokinase, their preparation and use
DE10210590A1 (de) * 2002-03-11 2003-10-02 Curacyte Ag Hemmstoffe des Gerinnungsfaktors Xa, ihre Herstellung und Verwendung
DE10212555A1 (de) 2002-03-15 2003-09-25 Univ Schiller Jena Verwendung von Hemmstoffen des Gerinnungsfaktors Xa als Wirkstoffe zur Erkennung und Unterdrückung des Wachstums maligner Tumore sowie der von diesen ausgehenden Metastasierung
DE10225876A1 (de) * 2002-06-11 2003-12-24 Wilex Ag Guanidinophenylalaninverbindungen als Urokinase-Inhibitoren
US7718406B2 (en) * 2002-10-04 2010-05-18 Dsm Ip Assets B.V. Substrates for TAFI (A)
DE10301300B4 (de) * 2003-01-15 2009-07-16 Curacyte Chemistry Gmbh Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein
DE10322191B4 (de) * 2003-05-16 2014-02-27 The Medicines Company (Leipzig) Gmbh N-sulfonylierte Aminosäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung
DE10323898A1 (de) * 2003-05-26 2004-12-23 Wilex Ag Hydroxyamidin- und Hydroxyguanidin-Verbindungen als Urokinase-Hemmstoffe
DE10342108A1 (de) * 2003-09-11 2005-04-14 Curacyte Chemistry Gmbh Basisch-substituierte Benzylaminanaloga als Inhibitoren des Gerinnungsfaktors Xa, ihre Herstellung und Verwendung
DE102005044319A1 (de) * 2005-09-16 2007-03-22 Curacyte Chemistry Gmbh 2-(Aminomethyl)-5-Chlor-Benzylamid-Derivate und ihre Verwendung als Hemmstoffe des Gerinnungsfaktors Xa
DE102006050672A1 (de) 2006-10-24 2008-04-30 Curacyte Discovery Gmbh Hemmstoffe des Plasmins und des Plasmakallikreins

Also Published As

Publication number Publication date
AU2007308421A1 (en) 2008-05-02
NO20091647L (no) 2009-07-14
US20100022781A1 (en) 2010-01-28
EA018998B1 (ru) 2013-12-30
JP2010507610A (ja) 2010-03-11
EP2054380B8 (de) 2013-10-30
CN101541742A (zh) 2009-09-23
EP2502906A3 (de) 2013-05-08
US8207378B2 (en) 2012-06-26
EP2054380B1 (de) 2013-09-11
EA200970397A1 (ru) 2009-10-30
WO2008049595A9 (de) 2009-01-29
US8410310B2 (en) 2013-04-02
JP5356237B2 (ja) 2013-12-04
DE102006050672A1 (de) 2008-04-30
BRPI0718286A2 (pt) 2013-11-19
US20130165510A1 (en) 2013-06-27
AU2007308421B2 (en) 2012-05-03
US20120225913A1 (en) 2012-09-06
CA2667507A1 (en) 2008-05-02
NZ577008A (en) 2012-02-24
ES2439244T3 (es) 2014-01-22
CA2667507C (en) 2015-04-21
WO2008049595A1 (de) 2008-05-02
EP2054380A1 (de) 2009-05-06
US8513461B2 (en) 2013-08-20
EP2502906A2 (de) 2012-09-26
MX2009004320A (es) 2009-08-28

Similar Documents

Publication Publication Date Title
ES2439244T8 (es) Inhibidores de serina proteasa tipo tripsina, su preparación y uso
LTPA2017010I1 (lt) Proteazomos inhibitoriai
ATE530554T1 (de) Serinprotease-hemmer
CY2015014I1 (el) Μακροκυκλικοι αναστολεις της πρωτεασης σερινης της ηπατιτιδας c
CR10847A (es) Compuesto heteromonociclico y uso del mismo
DE602007002746D1 (de) Steinzerkleinerungsvorrichtung
BRPI0807547A2 (pt) Inibidores de aspartil protease hetercíclicos
DE602006015876D1 (de) Schnellkupplung
DE602005005527D1 (de) Verschlussdüse
BRPI0811052A2 (pt) Composições de proteção de isquemia/reperfusão e métodos de uso.
BRPI0821668A2 (pt) Uso
BRPI0720124A2 (pt) Composições farmacêuticas e seus métodos de uso.
BRPI0813627A2 (pt) Peptídio antimicrobiano, composições e métodos de uso
CR10725A (es) Compuestos de pirazolina y su uso y composiones farmaceuticas
FR2903164B1 (fr) Raccord rapide
BRPI0717411A2 (pt) Uso de inibidores de iap
EP2224801A4 (en) MACROCYCLIC INHIBITORS OF THE OXIMYL TYPE OF HEPATITIS C VIRUS SERINE PROTEASE
BRPI0813683A2 (pt) composto amina e uso farmacêutico do mesmo
DE602005000475D1 (de) Schnellkupplung
DE602005019525D1 (de) Verschlussdüse
DK2032535T3 (da) Spiro-cycliske nitriler som protease-inhibitorer
FI20095499A0 (fi) Sieniperäinen seriiniproteaasi ja sen käyttö
ATE429417T1 (de) Hiv-protease-inhibitoren
FI20055692A (fi) Uusia entsyymejä
BRPI0719189A2 (pt) uso de ciclosporinas modificadas